Neuspera Medical® Announces FDA Clearance of its System for Peripheral Nerve StimulationFirst-of-its-kind, leadless micro-implant for chronic peripheral nerve pain management
SAN JOSE, Calif., April 18, 2023 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system. The system is comprised of a micro-implant that delivers neurostimulation therapy through a wireless platform including a wearable transmitter and iPad-based clinician programmer.
The Neuspera system delivers peripheral nerve stimulation (PNS) through a wireless, less invasive, and more versatile platform than commercially available technology. It is the first PNS device that offers an ultra-miniaturized option, which may allow for a better patient experience and greater procedural flexibility. It is 75x smaller than the smallest commercial implantable pulse generator and provides physicians the opportunity for deeper anatomical targets compared to current technologies available today.
“We look forward to bringing this innovative technology to physicians and patients in the U.S.,” commented Steffen Hovard, CEO of Neuspera Medical. “The Neuspera ultra-miniaturized system has the potential to revolutionize the way physicians treat patients battling chronic pain while restoring patients’ health and quality of life.”
In recent years, the growth of PNS technology and treatment has been significant, with advances in implantable device technology and an increasing number of clinical studies focused on developing new PNS therapies. PNS is becoming an increasingly important treatment option for managing chronic pain conditions, with the market expecting to experience significant growth due to factors including the increasing prevalence of chronic pain, advances in implantable device technology, and rising demand for alternative pain management therapies.
About Neuspera Medical
Neuspera Medical, Inc. is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses. The Neuspera platform is designed to provide patients and physicians with new, and potentially earlier, treatment options that are less invasive and more adaptable. These therapeutic alternatives aim to help patients restore their health and well-being for a better quality of life. For more information, please visit www.neuspera.com
Investor Relations and Media Contacts
Josh Cohen
Vice President, Market Development & Commercialization
Josh.Cohen@neuspera.com
SOURCE Neuspera Medical Inc.
Neuspera Hires Courtney Lane to Lead Clinical and Regulatory AffairsSAN JOSE, CA – February 1, 2023 — Neuspera® Medical, a medical device company developing miniaturized neuromodulation technology for patients with chronic illnesses, announces the hiring of Courtney Lane as Vice President, Clinical and Regulatory Affairs. The fast-growing early-stage company is progressing through enrollment of the second stage of its pivotal study (SANS-UUI) to evaluate the safety and efficacy of Neuspera’s technology in patients with urinary urgency incontinence associated with overactive bladder.
Dr. Courtney Lane has over 20 years of experience in neuromodulation device development and clinical trials. For the last 10 years, Dr. Lane worked as an independent consultant, working with cutting-edge medical device companies in the development of their devices and clinical and regulatory programs. Dr. Lane also served as Vice President of Clinical Affairs for Axonics Modulation Technologies, where she was responsible for the design and execution of the clinical program of a sacral neuromodulation device. Courtney was instrumental in the development of the Deep Brain Stimulation program at Boston Scientific, where she worked on all aspects of device development, from R&D and test designs to clinical trial designs and regulatory submissions. She then served as the Director of Clinical Science and Strategy, overseeing the development of Boston Scientific Neuromodulation’s clinical trial portfolio.
Steffen Hovard, CEO of Neuspera said: “We are excited to have Courtney Lane join Neuspera. Courtney brings a unique combination of skills and experiences that will help propel Neuspera forward – not to mention that she has a personality that makes it a pleasure to work with her.”
Dr. Lane earned her B.S.E.E. from Rice University, cum laude, and obtained her Ph.D. at the Massachusetts Institute of Technology in the Division of Health Sciences and Technology; she also worked as a researcher at Rice University, focusing on the development of hearing aid algorithms.
About Neuspera Medical
Neuspera Medical, Inc. is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses. The Neuspera platform, which will include the Nuvella system, will provide patients and physicians new, and potentially earlier, treatment options that are less invasive and more adaptable. These therapeutic alternatives aim to help patients restore their health and well-being for a better quality of life.
Investor Relations and Media Contacts
Josh Cohen
Vice President, Market Development & Commercialization
Josh.Cohen@neuspera.com
Neuspera Medical® announces first successful implant of the Nuvella™ System in the second phase of its sans-UUI IDE Clinical TrialStudy to support U.S. FDA approval of sacral neuromodulation device in patients with urinary urgency incontinence symptoms
SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced the first patient successfully implanted with the Nuvella™ system in its pivotal clinical trial (SANS-UUI). The procedure was performed by Dr. Jodi Michaels of Minnesota Urology, St. Paul, MN. The study will evaluate the safety and efficacy of the Nuvella system, designed to treat overactive bladder (OAB) with sacral neuromodulation (SNM) in patients with urinary urgency incontinence (UUI) symptoms.
Photo (left to right): Alex Yeh, Neuspera Founder & CTO, Dr. Jodi Michaels of Minnesota Urology and Steven Siegel, Neuspera CMO
“I am excited to be a part of the initial cases and for the potential of this innovative technology to treat my OAB patients in a less invasive and more adaptable way than current devices,” stated Dr. Jodi Michaels. “This system has the ability to treat UUI symptoms with the smallest available implant, significantly improving the patient experience.”
The prospective, multi-center, single-arm study will enroll 145 patients globally. The feasibility phase results of SANS-UUI were first presented at the annual meeting of the American Urological Association (AUA) in September 2021 and again at the winter meeting of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) in 2022. In 34 patients implanted with the Nuvella system, 90% of subjects demonstrated a 50% improvement in UUI symptoms at 6 and 12 months with two hours of daily stimulation, while 52% were completely dry at the 12-month visit.
Sacral neuromodulation is a proven therapy for the treatment of UUI that can significantly improve quality of life in patients suffering from this condition. The Nuvella system delivers neuromodulation therapy through a wireless, less invasive, and more versatile platform than commercially available technology. Nuvella is the first sacral neuromodulation device that offers this ultra-miniaturized option, which may allow for a better patient experience and greater procedural flexibility.
“We are pleased to enroll the first patients in our pivotal SANS-UUI trial, an important milestone for the company. Kicking off enrollment builds on the strong momentum from our feasibility experience,” commented Steffen Hovard, CEO of Neuspera Medical. “This technology has the potential to revolutionize the way physicians utilize SNM therapy to treat patients battling chronic conditions, while restoring patients’ health and quality of life.”
Overactive bladder (OAB) is a common medical disorder affecting roughly 1 in 6 adults.1 Symptoms of OAB include sudden, uncontrolled need or urge to urinate (most common), urine leakage, and need to pass urine many times during the night. The worldwide OAB treatment market size was 1,192.5M in 2020 and is experiencing tremendous growth due to increasing prevalence of chronic conditions.2
About Neuspera Medical
Neuspera Medical, Inc. is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses. The Neuspera platform, which includes the Nuvella system, will provide patients and physicians new, and potentially earlier, treatment options that are less invasive and more adaptable. These therapeutic alternatives aim to help patients restore their health and well-being for a better quality of life. For more information, please visit
www.neuspera.comInvestor Relations and Media Contacts
Josh Cohen
Vice President, Market Development & Commercialization
Josh.Cohen@neuspera.com
SOURCE Neuspera Medical Inc.
Neuspera Medical® Appoints Steffen Hovard as CEOHovard brings a wealth of medical device senior leadership experience to the company as it works to advance sacral neuromodulation therapies
SAN JOSE, Calif., Sept. 6, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable medical device technology for patients with chronic illness, today announced the hiring of seasoned medtech executive, Steffen Hovard as Chief Executive Officer. He joins as the company recently began enrollment of the second phase of its U.S. pivotal clinical trial (SANS-UUI). The study will evaluate the safety and efficacy of Neuspera’s Nuvella™ system designed to treat patients with urinary urgency incontinence (UUI), which is a symptom of overactive bladder (OAB).
“I am delighted to have Steffen join and lead Neuspera as we look to bring our therapy platform to patients struggling with debilitating conditions such as UUI,” commented Mudit Jain, of Treo Ventures. “He is an accomplished executive with an impressive record of leading multiple functions and driving significant growth in the urology space.”
Most recently, Hovard served as the President of Coloplast Interventional Urology, with leadership responsibility for four business areas within urological devices (class I, II, and III) including 900 employees across 19 countries. Steffen also serves as a board member for several companies in the medical device industry.
“I am excited to join Neuspera at this important time as the company builds momentum and clinical evidence for the Nuvella system,” stated Steffen Hovard, CEO of Neuspera Medical. “Sacral neuromodulation (SNM) is a proven therapy for the treatment of UUI which can significantly improve quality of life in patients suffering from this condition. Nuvella is the first sacral neuromodulation device that offers an ultra-miniaturized option, which aims to provide a better patient experience and greater procedural versatility. I look forward to working with a world-class team to bring this important technology to market.”
About Neuspera Medical
Neuspera Medical, Inc. is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses. The Neuspera platform, which will include the Nuvella system, will provide patients and physicians new, and potentially earlier, treatment options that are less invasive and more adaptable. These therapeutic alternatives aim to help patients restore their health and well-being for a better quality of life. To learn more visit
www.neuspera.com.
Investor Relations and Media Contacts
Josh Cohen
Vice President, Market Development & Commercialization
Josh.Cohen@neuspera.com
SOURCE Neuspera Medical Inc.
Neuspera Announces Leadership Expansion with the Addition of New CMOSan Jose, CA – August 4, 2022– Neuspera® Medical, a medical device company developing implantable medical device technology for patients battling chronic illness, today announced the hiring of Steven Siegel, MD, as Chief Medical Officer. Dr. Siegel joined Neuspera as the company recently began enrollment of the second phase of their pivotal clinical trial (SANS-UUI). The company presented initial, positive results from the feasibility phase at the American Urologic Association (AUA) 2021 annual meeting and at the winter meeting of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) in February of this year.
“We are excited to welcome Steven to the Neuspera team. He has an exceptional background, proven leadership ability, and deep domain expertise and will add tremendous value to the company moving forward as we build and scale for clinical and commercial operations,” said Neuspera board member Lori Hu from Vertex Ventures. “His wealth of knowledge and industry experience will be critical in guiding our strategic plan as we accelerate the pivotal trial and prepare for future milestones.”
Dr. Siegel has been practicing urology for over 35 years and is an internationally recognized expert and pioneer in the evolution of sacral neuromodulation. He participated in multi-center clinical trials with UroSystems in the late 1980s, when he was the Head of the Section of Female Urology and Urodynamics at the Cleveland Clinic. He participated in the pivotal “103” trials, which led to Interstim’s original approval for the indication of urinary urge incontinence (UUI) in 1997. He was a founding member of the International Society of Pelvic Neuromodulation, which later merged with the Society of Female Urology and Urodynamics. More recently, he was the national principal Investigator for the InSite trial, and lead author in numerous publications related to the study. He has recently retired from his clinical practice and served as the Director of the Minnesota Urology Centers for Female Urology and Continence Care since 1993.
“I am very excited to join a pioneering company like Neuspera and its endeavor to provide relief for patients battling the life-limiting symptoms of urinary urgency incontinence,” said Dr. Siegel. “I am passionate about revolutionizing neuromodulation treatment to truly transform how patients and physicians address chronic illness.”
About Neuspera Medical
Neuspera Medical, Inc. is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses. The Neuspera platform, which will include the Nuvella system, will provide patients and physicians new, and potentially earlier, treatment options that are less invasive and more adaptable. These therapeutic alternatives aim to help patients restore their health and well-being for a better quality of life.
Investor Relations and Media Contacts
Josh Cohen
Vice President, Market Development & Commercialization
Josh.Cohen@neuspera.com
Neuspera Medical Completes First Implants of its Neuromodulation Device in its two-stage Pivotal Clinical Trial to treat Urinary Urgency IncontinenceUltra-Miniaturized Device is Smallest-Known Sacral Nerve Implant
SAN JOSE, Calif., July 20, 2021 /PRNewswire/ — Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures. Lori Hu, a Managing Director at Vertex Ventures HC and Mudit K. Jain, Ph.D. Managing Partner, Treo Ventures, joined the Board of Directors. Returning Series A and Series B investors include Action Potential Venture Capital and Windham Venture Partners. The proceeds will fund the company’s SANS-UUI pivotal clinical study of its miniaturized implantable neuromodulation technology platform for use in subjects with Urinary Urgency Incontinence, a symptom of overactive bladder (OAB).
Neuspera Medical Inc. is a medical device company that leverages both exclusively licensed and proprietary power transfer techniques to engineer miniaturized neuromodulation technologies – sometimes referred to as bioelectronic medicines. Neuspera’s hermetically sealed implantable modules are more than 100 times smaller than neuromodulation devices using a traditional implanted battery power source and may reduce implant procedure complexity, patient complication, and post-surgical pain.
“Vertex Ventures HC is focused on enabling transformative solutions that help to improve the quality of human life.” said Lori Hu of Vertex Ventures HC. “We see the Neuspera platform as a catalyst for bringing the known thereapeutic benefits of implantable devices to a significantly broader population of deserving patients.”
“Neuspera is leveraging meaningful clinical experience to accelerate the development of its therapy platform that has the potential to significantly impact the lives of millions of patients. We are extremely excited to be part of the next phase of Neuspera’s growth, ” said Mudit K. Jain, PhD of Treo Ventures.
“We are excited to see the first cohort of patients experiencing the known benefits of sacral nerve stimulation through the use of our ultra-miniaturized neuromodulation platform – driven by the support of the physician investigators in the SANS-UUI clinical trial.” said Milton M. Morris, Ph.D., President & CEO of Neuspera Medical. “We are excited to continue our focused efforts on enabling access to the known benefits of neuromodulation to patients who are struggling with chronic and debilitating medical conditions.”
About Neuspera
Neuspera Medical, Inc. (San Jose, CA) is committed to developing implantable medical device technology that will improve lives of patients battling with chronic illness. The company is leveraging its’ proprietary Mid-Field Powering Technology, which allows for devices that are significantly smaller, implanted deeper, and may prove to be more reliable than other miniaturized neuromodulation technologies. This technology platform will provide patients and physicians new, and potentially earlier treatment options that are less invasive and more adaptable.
Investor Relations: www.Neuspera.com
About Vertex Ventures HC
Vertex Ventures HC (Palo Alto, CA) invests in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health. The Vertex portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. Vertex will take an active role in their portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. The global investment professionals at Vertex bring deep scientific, medical and business knowledge to every investment they make.
About Treo Ventures
The Treo team brings more than 80 years of cumulative healthcare experiences in investing and operational roles. Treo has invested globally in more than 60 companies through multiple market cycles. The team has worked together on a number of healthcare investments over the last 12 years prior to forming Treo Ventures. The Treo team has been involved in some of the premium healthcare companies bringing novel technologies to market. With over 80 years of combined operational and investing experiences across early and commercial stage companies, Treo team has played an active and important role from founding companies to liquidity via trade sales to multiple strategics and IPOs. Treo’s experiences on private and public company boards gives them a unique vantage point in their active involvement with portfolio companies. In addition, their scientific and commercial backgrounds along with global relationships have helped them play an important role in consistently building some of the most successful healthcare companies over last two decades.
SOURCE Neuspera Medical Inc.
Related Links
https://neuspera.com/
Neuspera Medical Announces Close of a $65M Series C Equity FinancingSAN JOSE, Calif., July 20, 2021 /PRNewswire/ — Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures. Lori Hu, a Managing Director at Vertex Ventures HC and Mudit K. Jain, Ph.D. Managing Partner, Treo Ventures, joined the Board of Directors. Returning Series A and Series B investors include Action Potential Venture Capital and Windham Venture Partners. The proceeds will fund the company’s SANS-UUI pivotal clinical study of its miniaturized implantable neuromodulation technology platform for use in subjects with Urinary Urgency Incontinence, a symptom of overactive bladder (OAB).
Neuspera Medical Inc. is a medical device company that leverages both exclusively licensed and proprietary power transfer techniques to engineer miniaturized neuromodulation technologies – sometimes referred to as bioelectronic medicines. Neuspera’s hermetically sealed implantable modules are more than 100 times smaller than neuromodulation devices using a traditional implanted battery power source and may reduce implant procedure complexity, patient complication, and post-surgical pain.
“Vertex Ventures HC is focused on enabling transformative solutions that help to improve the quality of human life.” said Lori Hu of Vertex Ventures HC. “We see the Neuspera platform as a catalyst for bringing the known thereapeutic benefits of implantable devices to a significantly broader population of deserving patients.”
“Neuspera is leveraging meaningful clinical experience to accelerate the development of its therapy platform that has the potential to significantly impact the lives of millions of patients. We are extremely excited to be part of the next phase of Neuspera’s growth, ” said Mudit K. Jain, PhD of Treo Ventures.
“We are excited to see the first cohort of patients experiencing the known benefits of sacral nerve stimulation through the use of our ultra-miniaturized neuromodulation platform – driven by the support of the physician investigators in the SANS-UUI clinical trial.” said Milton M. Morris, Ph.D., President & CEO of Neuspera Medical. “We are excited to continue our focused efforts on enabling access to the known benefits of neuromodulation to patients who are struggling with chronic and debilitating medical conditions.”
About Neuspera
Neuspera Medical, Inc. (San Jose, CA) is committed to developing implantable medical device technology that will improve lives of patients battling with chronic illness. The company is leveraging its’ proprietary Mid-Field Powering Technology, which allows for devices that are significantly smaller, implanted deeper, and may prove to be more reliable than other miniaturized neuromodulation technologies. This technology platform will provide patients and physicians new, and potentially earlier treatment options that are less invasive and more adaptable.
Investor Relations: www.Neuspera.com
About Vertex Ventures HC
Vertex Ventures HC (Palo Alto, CA) invests in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health. The Vertex portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. Vertex will take an active role in their portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. The global investment professionals at Vertex bring deep scientific, medical and business knowledge to every investment they make.
About Treo Ventures
The Treo team brings more than 80 years of cumulative healthcare experiences in investing and operational roles. Treo has invested globally in more than 60 companies through multiple market cycles. The team has worked together on a number of healthcare investments over the last 12 years prior to forming Treo Ventures. The Treo team has been involved in some of the premium healthcare companies bringing novel technologies to market. With over 80 years of combined operational and investing experiences across early and commercial stage companies, Treo team has played an active and important role from founding companies to liquidity via trade sales to multiple strategics and IPOs. Treo’s experiences on private and public company boards gives them a unique vantage point in their active involvement with portfolio companies. In addition, their scientific and commercial backgrounds along with global relationships have helped them play an important role in consistently building some of the most successful healthcare companies over last two decades.
SOURCE Neuspera Medical Inc.
Related Links
https://neuspera.com/
Neuspera Medical Receives Investigational Device Exemption for Its Ultra-Miniaturized Implantable DeviceRegulatory Approval to Start Phase I of its Pivotal Trial
SAN JOSE, Calif., Dec. 10, 2019 /PRNewswire/ — Neuspera Medical Inc., a clinical stage, private, venture capital backed neuromodulation company, announced the receipt of an Investigational Device Exemption (IDE) from the FDA – enabling the company to conduct the first long-term clinical trial of its ultra-miniaturized neuromodulation platform. An MRI Conditional version of Neuspera’s wirelessly powered implant designed for use as a sacral nerve stimulator will be studied for treatment of Urinary Urge Incontinence (UUI) – a prevalent form of Over Active Bladder.
“The Neuspera team continues to take meaningful steps to bringing their novel technology platform to patients battling the symptoms of UUI,” said Adam Fine, Founder & Managing Partner of Windham Venture Partners – a major investor in Neuspera Medical. “The Investigational Device Exemption marks a key milestone in the company’s lifecycle and speaks to the maturity of the medical device platform. We look forward to more applications in the future.”
The Neuspera platform leverages proprietary power transfer methods that enable miniaturization of implantable devices – sometimes referred to as bioelectronic medicines. Neuspera’s hermetically sealed implantable modules are more than 100 times smaller than traditional neuromodulation devices and is expected to reduce implant procedure complexity, patient post-surgical pain and complication. Traditional neuromodulation devices require an implanted battery power source and are therefore larger and require more complex and invasive implantation procedures.
“Urinary Urge Incontinence can be a significant burden for patients who struggle daily with the perceived loss of control and the unpredictable nature of the condition,” said Milton M. Morris, Ph.D., President & CEO of Neuspera. “The approval to conduct our clinical trial in this important and underserved population of patients is a key step toward our goal of improving their care and outcome.”
About Neuspera
Neuspera Medical, Inc. (San Jose, CA) is committed to developing implantable medical device technology that will improve the lives of patients battling with chronic illness or dysfunction. The company is leveraging its Fourth Generation Mid-Field Powering Technology, which allows for devices that are significantly smaller, that may be implanted deeper, and may be more reliable than other miniaturized neuromodulation technologies. This technology platform is designed to provide patients and physicians new, and potentially earlier treatment options that are less invasive and more adaptable.
Investor Relations: www.Neuspera.com
About Windham Venture Partners
Founded in 2006, Windham Venture Partners is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and healthcare IT / digital health. Windham partners with visionary founders and entrepreneurs commercializing game-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors.
Learn More about Windham Venture Partners: www.windhamvp.com
SOURCE Neuspera Medical Inc.
Neuspera Medical has raised a new total of $26 million in equity financing, following the closing of the second tranche of its series B round, to help fund clinical testing programs for its neuromodulation implants.
Each of the round’s original investors returned to participate, including 6 Dimensions Capital, Action Potential Venture Capital, Windham Venture Partners, Delta Capital, Purple Arch Ventures and others.
The second and final $12 million tranche was triggered after the company met development and regulatory objectives, the San Jose, California-based company said in a statement. The series B round first closed in January 2018.
Neuspera is focused on developing techniques to transfer power to implants from outside the body, using electromagnetic waves—to allow for smaller, sealed implant designs, compared to battery-powered neuromodulation devices. The company was first founded in 2014 as Vivonda Medical.
The company believes it can use the structure of the human body to help guide and focus electromagnetic waves, in order to power implants located deeper in muscle and bone, while maintaining a device smaller than a few millimeters in size.
The implanted electrical stimulators can then help maintain heartbeats or treat neurological diseases, as well as help power other devices, Neuspera said.
Electroceuticals Startup Neuspera Raises $8M to Back Tiny, Injectable Neuromodulation TechNeuspera Medical had been working under the radar for some time on about $1 million in angel financing. Now, it’s raised an $8 million Series A financing after bringing in a high-profile exec to lead its effort. The Santa Clara, CA-based startup is aiming for a futuristic field that already has substantial strategic interest: electroceuticals.
GlaxoSmithKline ($GSK) declared its interest in electroceuticals, also known as bioelectronics, a few years ago. The idea is that miniature devices can be used to modulate the electrical impulses in the body, thereby triggering biochemical processes that are more typically manipulated via biopharmaceuticals. The end game is to replace drug therapies by inducing the body to heal itself in major illnesses that could include diabetes, asthma, hypertension, arthritis, pain and even cancer.
The biopharma has put its money where its mouth is with a couple of financing initiatives including a $50 million venture fund. GSK has funded at least 33 electroceuticals, mostly in very early research stages.
Neuspera claims that its implant is more than 100 times smaller than other neuromodulation devices. It expects its miniaturized injectable neuromodulation technology could treat patients with chronic illnesses. Its small form factor is expected to reduce procedure complexity and time as well as patient complications and post-surgical pain. The tech is powered by the company’s MidField technology.
It’s not quite clear yet if NeuSpera is aiming for the more traditional function of neuromodulation, pain management, with a smaller form factor–or if it’s actually seeking to address tackle underlying disease processes. Either way, it’s staked itself out as an electroceuticals company.
The company was founded in 2014 as Vivonda Medical. Last August, it brought in former Cyberonics SVP of R&D Milton Morris. He was first tasked with a Series A fundraising. Morris left Cyberonics in the shake-up after the $3 billion merger with Sorin to create LivaNova ($LIVN).
“It is a privilege to be in a position to positively impact human lives through medical technology–a privilege that I take seriously,” said Morris in a statement when he was appointed as the startup’s CEO. “NeuSpera has the opportunity to fundamentally change the way neuromodulation therapy is delivered. I look forward to realizing its great potential.”
– Here is the SEC filing
